Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

A retrospective cohort study using a UK digital prescribing service found that tirzepatide was associated with substantial weight loss: mean -13.5% at 6 months and -17.4% at 12 months. Most patients achieved clinically meaningful weight loss, more regular ordering was linked to greater loss, and many reported improvements in mood and mobility.

Journal article — Retrospective cohort study. Population: Adults with obesity initiating tirzepatide via a UK digital prescribing service. Sample size: 630 545 eligible patients. Follow-up: 12 months. Interventions: Tirzepatide.

Among 630,545 eligible patients (80.3% female, mean BMI 36.1 kg/m²), mean weight loss in those with recorded weights was -13.5% at 6 months (n = 270,309) and -17.4% at 12 months (n = 58,434). At 6 months, 89.9% achieved at least 5% weight loss and 72.1% achieved at least 10%. More regular ordering was associated with greater weight loss, and clinically meaningful outcomes were often achieved without escalation beyond intermediate doses. Treatment persistence was higher among patients from less deprived areas, who had 26.1% more prescription orders than those from the most deprived areas. Patient-reported improvements included mobility in 46.7%, mood in 45.9%, and reduced alcohol consumption in 26.7%.

This paper provides large real-world evidence on tirzepatide for obesity in a routine digital prescribing pathway, complementing clinical trial efficacy data. It is useful for researchers studying adherence, deprivation, and patient-reported outcomes with GLP-1-based therapies. It does not establish causal efficacy, safety beyond self-reported side effects, or a specific dosing protocol.

Key findings

• Mean weight loss was -13.5% at 6 months (n = 270,309) and -17.4% at 12 months (n = 58,434).
• At 6 months, 89.9% of patients achieved at least 5% weight loss and 72.1% achieved at least 10%.
• More regular ordering cadence was associated with greater weight loss.
• Patients from less deprived areas had 26.1% more prescription orders than those from the most deprived areas.
• Patient-reported improvements at 6 months included mobility in 46.7%, mood in 45.9%, and reduced alcohol consumption in 26.7%.
• Clinically meaningful outcomes were frequently achieved without escalation beyond intermediate doses.

Limitations

• Observational retrospective design cannot establish causality.
• No control group was used.
• Weight outcomes were self-reported, and outcome data were available for only a subset of patients at each time point.
• Findings from a UK digital prescribing service may not generalize to other care settings.

The record

• Journal: Diabetes, obesity & metabolism
• Published: 2026-08-06
• PMID: 42560020 — DOI: 10.1111/dom.71067
• Author countries: UK

Peptide profiles: Tirzepatide.

All indexed evidence: Tirzepatide trials & papers.

Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….